Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
it-hMSC in Ischemic Stroke
NCT04953663Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ischemia-tolerant mesenchymal stem cells in ischemic stroke, sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04953663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953663.